Urogen Pharma Ltd
NASDAQ:URGN
Intrinsic Value
UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. [ Read More ]
The intrinsic value of one URGN stock under the Base Case scenario is 18.83 USD. Compared to the current market price of 14.3 USD, Urogen Pharma Ltd is Undervalued by 24%.
Valuation Backtest
Urogen Pharma Ltd
Run backtest to discover the historical profit from buying and selling URGN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Urogen Pharma Ltd
Current Assets | 169.2m |
Cash & Short-Term Investments | 137m |
Receivables | 15.4m |
Other Current Assets | 16.8m |
Non-Current Assets | 9.1m |
Long-Term Investments | 4.5m |
PP&E | 2.4m |
Other Non-Current Assets | 2.3m |
Current Liabilities | 31.2m |
Accounts Payable | 6.5m |
Accrued Liabilities | 21.7m |
Other Current Liabilities | 3m |
Non-Current Liabilities | 212.3m |
Long-Term Debt | 98.6m |
Other Non-Current Liabilities | 113.8m |
Earnings Waterfall
Urogen Pharma Ltd
Revenue
|
82.7m
USD
|
Cost of Revenue
|
-9.4m
USD
|
Gross Profit
|
73.4m
USD
|
Operating Expenses
|
-138.9m
USD
|
Operating Income
|
-65.5m
USD
|
Other Expenses
|
-36.7m
USD
|
Net Income
|
-102.2m
USD
|
Free Cash Flow Analysis
Urogen Pharma Ltd
What is Free Cash Flow?
URGN Profitability Score
Profitability Due Diligence
Urogen Pharma Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Urogen Pharma Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
URGN Solvency Score
Solvency Due Diligence
Urogen Pharma Ltd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Urogen Pharma Ltd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
URGN Price Targets Summary
Urogen Pharma Ltd
According to Wall Street analysts, the average 1-year price target for URGN is 39.27 USD with a low forecast of 18.18 USD and a high forecast of 56.7 USD.
Ownership
URGN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
URGN Price
Urogen Pharma Ltd
Average Annual Return | -28.2% |
Standard Deviation of Annual Returns | 19.8% |
Max Drawdown | -87% |
Market Capitalization | 464.6m USD |
Shares Outstanding | 34 122 100 |
Percentage of Shares Shorted | 13.28% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Contact
IPO
Employees
Officers
The intrinsic value of one URGN stock under the Base Case scenario is 18.83 USD.
Compared to the current market price of 14.3 USD, Urogen Pharma Ltd is Undervalued by 24%.